SPOTLIGHT: Schering-Plough touts potential of new drug

Schering-Plough is bullish about its experimental anti-clotting drug, saying it could be a potentially transformational product that can significantly reduce the risk of heart attack and stroke without raising the risk of bleeding. The drug prevents thrombin, a clot-causing protein, from attaching to platelets. Report

Suggested Articles

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.

The appointment gives Sino-American biotech Brii the experience of a man who helped Gilead launch eight drugs in China in quick succession.